<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00284739</url>
  </required_header>
  <id_info>
    <org_study_id>HI-03HYoon-02</org_study_id>
    <nct_id>NCT00284739</nct_id>
  </id_info>
  <brief_title>Alteplase for Percutaneous Treatment of Loculated Abdominopelvic Abscesses</brief_title>
  <official_title>Alteplase for Percutaneous Treatment of Loculated Abdominopelvic Abscesses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaiser Permanente</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kaiser Permanente</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intracavitary injection of low dose alteplase into loculated abdominopelvic abscesses will
      reduce the duration of percutaneous drainage and increase the proportion of successful
      drainages.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The use of fibrinolytics for the percutaneous drainage of loculated pleural effusions has
      been shown to reduce the catheter dwell time and to improve drainage of the effusions.
      Abscesses in the abdomen and pelvis are often loculated which makes percutaneous drainage
      difficult. We hypothesize that the infusion of alteplase via a drainage catheter into the
      loculated abscess collections of the abdomen and pelvis will similarly decrease catheter
      dwell time and improve overall abscess drainage. The direct injection of Activase into
      abscess cavities utilizes a very low dose of drug within a closed environment which should
      not be associated with any significant risk of hemorrhage. To date, there does not appear to
      be a significant risk of systemic hemorrhagic complications associated with the use of
      intracavitary thrombolytics for the drainage of abdominopelvic abscesses although only a few
      such studies have been reported. We hope to prove that the use alteplase for intracavitary
      thrombolysis improves outcomes associated with percutaneous catheter drainage of loculated
      abscess collections without increasing complications or costs.

      The design of the trial will be as a single-center, prospective, open-label, randomized trial
      comparing the infusion of Activase versus saline for treatment of loculated abdominopelvic
      abscesses requiring percutaneous drainage. Patients with loculated abdominopelvic abscesses
      who are referred for percutaneous drainage will be eligible for this study. Patients will
      undergo standard placement of a 10-12 french percutaneous drain into their abscess cavity
      under computed tomography guidance. If the entire contents of the abscess cavity cannot be
      aspirated at the time of initial catheter placement, the abscess will be assumed to be
      loculated. The patient will then be randomized to have their abscess catheter irrigated twice
      a day with a volume of fluid approximately equal to the one-half the residual volume of the
      abscess. In the control group, the normal saline will be fluid instilled into the abscess
      cavity. The study group will receive Activase reconstituted in sterile water and then diluted
      to the appropriate volume with normal saline.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients Requiring Surgical Debridement for a Persistent Abscess Within 30 Days Following Initial Drainage</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Loculated Abscesses Which Completely Resolve With Percutaneous Drainage Alone at the First Follow-up CT Scan Performed 3 Days After Initial Drain Placement</measure>
    <time_frame>3 days</time_frame>
    <description>This is the percentage of participants in whom their loculated abscess completely resolve with percutaneous drainage at the time of the first followup CT performed at 3 days after start of the intervention and therefore do NOT require additional surgical intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration (in Days) of Percutaneous Drainage.</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>The total number of days that the drainage catheter was left in place from the time of randomization until the time of catheter removal. The maximum duration of measurement for this outcome was up to 30 days.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Abdominal Abscess</condition>
  <condition>Pelvic Abscess</condition>
  <arm_group>
    <arm_group_label>Alteplase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple Alteplase injection into the abscess collection to improve percutaneous drainage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple normal saline injection into the abscess collection to improve percutaneous drainage</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alteplase</intervention_name>
    <description>2mg or 4mg given twice daily for three days into loculated abscess</description>
    <arm_group_label>Alteplase</arm_group_label>
    <other_name>Activase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>saline</intervention_name>
    <description>saline injection twice daily for three days</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide written informed consent and comply with study assessments for the
             full duration of the study.

          -  Age &gt; 18 years

          -  Adult, non-gravid patients with loculated abdominopelvic abscesses immediately after
             percutaneous drainage will be eligible to participate. A loculated abscess is defined
             as an abscess whose contents cannot be completely drained at the time of initial
             catheter placement as documented on CT.

        Exclusion Criteria:

          -  Active internal bleeding, involving intracranial and retroperitoneal sites, or the
             gastrointestinal, genitourinary, or respiratory tracts

          -  History of stroke within 6 months

          -  Uncorrectable bleeding diathesis (INR &gt; 1.3 despite therapy)

          -  Recent intracranial or intraspinal surgery or trauma

          -  Pregnancy (positive pregnancy test)

          -  Pancreatic abscesses

          -  Any other condition that the investigator believes would pose a significant hazard to
             the subject if the investigational therapy were initiated

          -  Participation in another simultaneous medical investigation or trial

          -  Participation in another clinical investigation within previous 30 days of catheter
             placement

          -  Prior enrollment in the study

          -  Known allergy to Alteplase or any of its components
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyo-Chun Yoon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaiser Permanente Hawaii</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaiser Foundation Hospital</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2006</study_first_submitted>
  <study_first_submitted_qc>January 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2006</study_first_posted>
  <results_first_submitted>December 16, 2013</results_first_submitted>
  <results_first_submitted_qc>February 24, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 26, 2015</results_first_posted>
  <last_update_submitted>February 24, 2015</last_update_submitted>
  <last_update_submitted_qc>February 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abscess</mesh_term>
    <mesh_term>Abdominal Abscess</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Hospitalized patients with loculated abscess were enrolled</recruitment_details>
      <pre_assignment_details>All patients had undergone percutaneous drainage for abscess and loculation documented by residual fluid surrounding the catheter after initial drainage</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Alteplase</title>
          <description>Multiple Alteplase injection into the abscess collection to improve percutaneous drainage</description>
        </group>
        <group group_id="P2">
          <title>Saline</title>
          <description>Multiple normal saline injection into the abscess collection to improve percutaneous drainage</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Alteplase</title>
          <description>Multiple Alteplase injection into the abscess collection to improve percutaneous drainage</description>
        </group>
        <group group_id="B2">
          <title>Saline</title>
          <description>Multiple normal saline injection into the abscess collection to improve percutaneous drainage</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" spread="19"/>
                    <measurement group_id="B2" value="57" spread="20"/>
                    <measurement group_id="B3" value="52" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients Requiring Surgical Debridement for a Persistent Abscess Within 30 Days Following Initial Drainage</title>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Multiple Alteplase injection into the abscess collection to improve percutaneous drainage</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Multiple normal saline injection into the abscess collection to improve percutaneous drainage</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Requiring Surgical Debridement for a Persistent Abscess Within 30 Days Following Initial Drainage</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Loculated Abscesses Which Completely Resolve With Percutaneous Drainage Alone at the First Follow-up CT Scan Performed 3 Days After Initial Drain Placement</title>
        <description>This is the percentage of participants in whom their loculated abscess completely resolve with percutaneous drainage at the time of the first followup CT performed at 3 days after start of the intervention and therefore do NOT require additional surgical intervention.</description>
        <time_frame>3 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Multiple Alteplase injection into the abscess collection to improve percutaneous drainage</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Multiple normal saline injection into the abscess collection to improve percutaneous drainage</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Loculated Abscesses Which Completely Resolve With Percutaneous Drainage Alone at the First Follow-up CT Scan Performed 3 Days After Initial Drain Placement</title>
          <description>This is the percentage of participants in whom their loculated abscess completely resolve with percutaneous drainage at the time of the first followup CT performed at 3 days after start of the intervention and therefore do NOT require additional surgical intervention.</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration (in Days) of Percutaneous Drainage.</title>
        <description>The total number of days that the drainage catheter was left in place from the time of randomization until the time of catheter removal. The maximum duration of measurement for this outcome was up to 30 days.</description>
        <time_frame>Up to 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>Multiple Alteplase injection into the abscess collection to improve percutaneous drainage</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Multiple normal saline injection into the abscess collection to improve percutaneous drainage</description>
          </group>
        </group_list>
        <measure>
          <title>Duration (in Days) of Percutaneous Drainage.</title>
          <description>The total number of days that the drainage catheter was left in place from the time of randomization until the time of catheter removal. The maximum duration of measurement for this outcome was up to 30 days.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="4.5" upper_limit="7.5"/>
                    <measurement group_id="O2" value="11" lower_limit="8" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Alteplase</title>
          <description>Multiple Alteplase injection into the abscess collection to improve percutaneous drainage</description>
        </group>
        <group group_id="E2">
          <title>Saline</title>
          <description>Multiple normal saline injection into the abscess collection to improve percutaneous drainage</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hyo-Chun Yoon, MD,PHD</name_or_title>
      <organization>Kaiser Permanente</organization>
      <phone>8084327342</phone>
      <email>Hyo-Chun.Yoon@nsmtp.kp.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

